<?xml version="1.0" encoding="UTF-8"?>
<p>As specified in 
 <xref ref-type="sec" rid="sec2-pharmaceutics-12-00171">Section 2</xref>, the current antiviral therapy for HSV infection includes topical formulations of ACV that is unable permeate stratum corneum and target the virus site at the basal epidermis due to its polarity and solubility, leading to poor clinical efficacy due to delayed antiviral activity and sub-inhibitory concentrations [
 <xref rid="B100-pharmaceutics-12-00171" ref-type="bibr">100</xref>]. Nanotechnology strategies [
 <xref rid="B97-pharmaceutics-12-00171" ref-type="bibr">97</xref>] seem to facilitate the “admission fees” due to the rationally design and innovative functionalities of the synthesized nano-platforms as presented in 
 <xref ref-type="fig" rid="pharmaceutics-12-00171-f003">Figure 3</xref>.
</p>
